常茂生物(00954)公布中期业绩 股东应占亏损为2579万元 同比增长37.28%

智通财经网
Aug 18, 2025

智通财经APP讯,常茂生物(00954)公布2025年中期业绩,收入约2.72亿元,同比减少13.23%;归属于公司股东的亏损为2579万元,同比增长37.28%;每股亏损0.049元。

公告称,业绩下滑主要影响因素为:1、受地缘政治冲突、关税政策不确定性等外部因素干扰。此外,顺酐的下游产品需求逊于预期,新增产能释放导致供需格局变化,间接影响集团主要产品价格和盈利能力;及2、合并综合收益表中利息费用增加,因合资格资产的资本化利息支出金额减少。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10